Stay updated on Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe ClinicalTrials.gov page footer now identifies the site as revision v3.7.1 instead of v3.7.0.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe history now lists a new version (v3.7.0) and removes the previous (v3.6.6), representing an update to the recorded history rather than a change to the trial data.SummaryDifference0.1%

- Check45 days agoChange DetectedA new revision entry v3.6.6 was added to the study history, replacing the prior v3.6.5 entry in the visible history. No study data or participant-facing content is affected.SummaryDifference0.1%

- Check66 days agoChange DetectedThe history now lists revision v3.6.5, replacing the previous v3.6.4, indicating a new page version was published.SummaryDifference0.1%

- Check81 days agoChange DetectedThe Record History now shows Revision: v3.6.4, replacing the previous Revision: v3.6.3, indicating a minor update to the page’s historical record.SummaryDifference0.1%

- Check102 days agoChange DetectedThe history now adds Revision: v3.6.3 and removes Revision: v3.6.2, updating the page's revision trail.SummaryDifference0.1%

Stay in the know with updates to Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page.